TG Therapeutics released preliminary financials for 2025. They expect full year global revenue to be approximately $616 million, with Briumvi US net revenue contributing about $594 million. Q4 Briumvi revenue in the US came in at $182 million. Looking ahead to 2026, the company is guiding for total global revenue between $875 million and $900 million. They expect operating expenses to stay around $350 million. Management also mentioned upcoming data readouts for their IV and subcutaneous Briumvi programs later in 2026.